Cargando…

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD

BACKGROUND: Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies represents an established treatment for patients with severe eosinophilic asthma (SEA) but did not show clinical efficacy in patients with COPD. The objective of the present study was to evaluate treatment res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drick, Nora, Fuge, Jan, Seeliger, Benjamin, Speth, Milan, Vogel-Claussen, Jens, Welte, Tobias, Suhling, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original research articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589335/ https://www.ncbi.nlm.nih.gov/pubmed/36299360 http://dx.doi.org/10.1183/23120541.00207-2022

Ejemplares similares

Influence of anti-interleukin (IL)-5/anti-IL-5 receptor-α treatment on work productivity in patients with severe eosinophilic asthma
por: Drick, Nora, et al.
Publicado: (2023)

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response
por: Drick, Nora, et al.
Publicado: (2018)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
por: Drick, Nora, et al.
Publicado: (2020)

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2022)

The impact of anti-eosinophilic therapy on exercise capacity and inspiratory muscle strength in patients with severe asthma
por: Franceschi, Elisa, et al.
Publicado: (2023)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma
por: Plank, Pia Maria, et al.
Publicado: (2023)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor
Publicado: (1988)

Eosinophils, beyond IL-5
por: Esnault, Stephane, et al.
Publicado: (2021)

Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU
por: Barbarot, Nicolas, et al.
Publicado: (2022)

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
por: Bakakos, Agamemnon, et al.
Publicado: (2021)

Chronic progressive pulmonary paracoccidioidomycosis in a female immigrant from Venezuela
por: Kayser, Moritz, et al.
Publicado: (2019)

Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media
por: Chikumoto, Ayumi, et al.
Publicado: (2022)

Targeting IL-5 in COPD
por: Narendra, Dharani K, et al.
Publicado: (2019)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review
por: Patterson, Megan F, et al.
Publicado: (2015)

Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
por: Menzella, Francesco, et al.
Publicado: (2020)

Adherence is associated with a favorable outcome after lung transplantation
por: Bertram, Anna, et al.
Publicado: (2019)

Comparison of IL-33 and IL-5 family mediated activation of human eosinophils
por: Angulo, Evelyn L., et al.
Publicado: (2019)

Combining Biologics Targeting Eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in Allergic and Inflammatory Diseases
por: Pitlick, Mitchell M., et al.
Publicado: (2022)

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma
por: Farahani, Rahim, et al.
Publicado: (2014)

Evaluation of C-C Chemokine Ligand 5 (CCL5) Chemokine, Interleukin 5 (IL-5) Cytokine, and Eosinophil Counts as Potential Biomarkers in Saudi Patients with Chronic Asthma During Sandstorms
por: Alturaiki, Wael H
Publicado: (2020)

Effects of prednisolone on eosinophils, IL-5, eosinophil cationic protein, EG2+ eosinophils, and nitric oxide metabolites in the sputum of patients with exacerbated asthma.
por: Jang, A. S., et al.
Publicado: (2000)

Mouse resident lung eosinophils are dependent on IL‐5
por: Dolitzky, Avishay, et al.
Publicado: (2022)

Topical Nasal Anesthesia in Flexible Bronchoscopy – A Cross-Over Comparison between Two Devices
por: Fuehner, Thomas, et al.
Publicado: (2016)

Interleukin-5 and IL-5 receptor in health and diseases
por: TAKATSU, Kiyoshi
Publicado: (2011)

IL-5 and IL-6 are increased in the frontal recess of eosinophilic chronic rhinosinusitis patients
por: Kubota, Kazunori, et al.
Publicado: (2017)

The Prospects of an Active Vaccine Against Asthma Targeting IL-5
por: Bachmann, Martin F., et al.
Publicado: (2018)

Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma
por: Jang, Jae-Hyuk, et al.
Publicado: (2020)

Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells
por: Chen, Sisi, et al.
Publicado: (2022)

Cumulative corticosteroid-sparing effect of anti-interleukin-5/5Ra in eosinophilic asthma
por: Kroes, Johannes A., et al.
Publicado: (2022)

IL-5 and GM-CSF, but Not IL-3, Promote the Proliferative Properties of Inflammatory-like and Lung Resident-like Eosinophils in the Blood of Asthma Patients
por: Palacionyte, Jolita, et al.
Publicado: (2022)

Susceptibility to L. sigmodontis infection is highest in animals lacking IL-4R/IL-5 compared to single knockouts of IL-4R, IL-5 or eosinophils
por: Frohberger, Stefan J., et al.
Publicado: (2019)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

Anti‐interleukin 5 antibody is effective for not only severe asthma and eosinophilic pneumonia but also eosinophilic bronchiolitis
por: Tomyo, Fuminori, et al.
Publicado: (2018)

Anti-IL5 therapy for asthma and beyond
por: Mukherjee, Manali, et al.
Publicado: (2014)

Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease
por: Greenfeder, Scott, et al.
Publicado: (2001)

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma
por: Roufosse, Florence
Publicado: (2018)

Pathogenesis of allergen-induced eosinophilic esophagitis is independent of Interleukin (IL)-13
por: Niranjan, Rituraj, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_og02jnabhlgfcsqov30biv2qhn